Research Analysts Issue Forecasts for ORIC FY2025 Earnings

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of ORIC Pharmaceuticals in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal expects that the company will post earnings per share of ($2.32) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($1.84) per share.

ORIC Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.01).

Several other equities analysts have also weighed in on ORIC. Wedbush restated an “outperform” rating and issued a $20.00 price objective on shares of ORIC Pharmaceuticals in a report on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of ORIC Pharmaceuticals in a research note on Monday, January 13th. Finally, Wells Fargo & Company initiated coverage on ORIC Pharmaceuticals in a report on Thursday, October 31st. They issued an “overweight” rating and a $20.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, ORIC Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $18.29.

ORIC Pharmaceuticals Trading Up 4.8 %

ORIC Pharmaceuticals stock opened at $10.34 on Thursday. ORIC Pharmaceuticals has a 1 year low of $6.33 and a 1 year high of $16.65. The company’s 50-day moving average is $8.97 and its two-hundred day moving average is $9.54. The company has a market cap of $729.69 million, a PE ratio of -5.74 and a beta of 1.18.

Hedge Funds Weigh In On ORIC Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its stake in shares of ORIC Pharmaceuticals by 53.7% in the 2nd quarter. Rhumbline Advisers now owns 92,702 shares of the company’s stock valued at $655,000 after purchasing an additional 32,402 shares during the period. American Century Companies Inc. raised its position in ORIC Pharmaceuticals by 15.1% in the 2nd quarter. American Century Companies Inc. now owns 84,201 shares of the company’s stock valued at $595,000 after buying an additional 11,034 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in ORIC Pharmaceuticals by 190.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 466,662 shares of the company’s stock valued at $3,299,000 after acquiring an additional 305,860 shares in the last quarter. XTX Topco Ltd acquired a new position in ORIC Pharmaceuticals during the 2nd quarter worth approximately $153,000. Finally, Profund Advisors LLC grew its stake in shares of ORIC Pharmaceuticals by 23.6% during the 2nd quarter. Profund Advisors LLC now owns 21,861 shares of the company’s stock worth $155,000 after acquiring an additional 4,175 shares in the last quarter. 95.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Jacob Chacko sold 24,660 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $204,184.80. Following the completion of the transaction, the chief executive officer now owns 778,648 shares in the company, valued at $6,447,205.44. This represents a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Pratik S. Multani sold 8,850 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $8.28, for a total transaction of $73,278.00. Following the sale, the insider now directly owns 46,765 shares of the company’s stock, valued at $387,214.20. This represents a 15.91 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 42,361 shares of company stock valued at $350,749. 5.55% of the stock is owned by company insiders.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.